Strategies to overcome intrinsic resistance in Stenotrophomonas maltophilia: In vitro activity of aztreonam/avibactam, cefiderocol, and cefepime–zidebactam
Abstract
Abstract Purpose: To evaluate the in vitro activity of cefiderocol, aztreonam/avibactam, and cefepime/zidebactam against contemporary clinical Stenotrophomonas maltophilia isolates and to assess bactericidal activity using time-kill analyses.
Methods:: A total of 216 nonduplicate clinical S. maltophilia isolates collected between 2018 and 2024 from five tertiary care hospitals in India, were studied. MICs of trimethoprim/sulfamethoxazole (TMP-SMX), levofloxacin, minocycline, cefiderocol, aztreonam/avibactam, and cefepime/zidebactam were determined by broth microdilution according to CLSI guidelines. Cefiderocol was tested in iron-depleted cation-adjusted Mueller–Hinton broth. Aztreonam/avibactam was tested with avibactam at 4 mg/L, and cefepime/zidebactam at a 1:1 ratio. PK/PD breakpoints of ≤ 8 mg/L and ≤ 64 mg/L were applied for aztreonam/avibactam and cefepime/zidebactam, respectively. Time–kill assays were performed at 1× MIC against two representative isolates and ten additional isolates spanning cefepime/zidebactam MICs of 4–64 mg/L.
Results:: Cefiderocol inhibited 96.8% of isolates at MICs ≤ 1 mg/L (MIC50/MIC90 ≤ 0.12/1 mg/L). Susceptibility rates were 95.8% for aztreonam/avibactam and 99.5% for cefepime/zidebactam. TMP-SMX and levofloxacin each inhibited 91.7% of isolates, while minocycline susceptibility was 92.6%. The three novel agents retained activity against most isolates non-susceptible to comparators. In time–kill assays, cefiderocol, aztreonam/avibactam, and…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.